^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GEN-009

    i
    Associations
    News

    Trials

    Company:
    Genocea
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine (NCT03633110)
    Phase 1/2
    Genocea Biosciences, Inc.
    Completed
    Last update posted :
    04/19/2022
    Initiation :
    08/29/2018
    Primary completion :
    12/08/2021
    Completion :
    02/28/2022
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • GEN-009